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Case presentation
A 46-year-old mother of two was first admitted to the Rambam
Hospital 14 years ago because of severe itching. For the 11 years prior
to that admission, she had experienced generalized itching, dry mouth
and eyes, and episodic jaundice with dark urine and light stools. On
physical examination she was well nourished and had a blood pressure
of 140/90 mm Hg. Her skin had an olive hue and revealed many new and
old scratch marks. The lower edge of the liver was palpated 3 cm below
and that of the spleen 2 cm below the costal margin. Laboratory studies
were unremarkable except for a total bilirubin of 1.6 mg/dl and an
alkaline phosphatase 2.5 times the upper limit of normal. Administra-
tion of eholestyramine, 4 g/day, produced relief from the itching.
Intravenous cholangiography and intravenous pyelography were nor-
mal. For the following nine years, her condition was stable except for
recurrent jaundice.
She was hospitalized agaln 5 years ago. Physical examination re-
vealed mild jaundice and clubbing of the fingers. The blood pressure
was 130/90mm Hg. The liver and the spleen were palpable 14cm and 4
cm below the costal margin, respectively. Endoscopy revealed esopha-
geal variees. Total serum bilirubin was 3.7 mg/dI (60% conjugated);
alkaline phosphatase, three times the upper limit of normal; and serum
glutamic oxaloacetie transaminase, 54 U (normal, below 40 U). Serum
albumin was 4.1 Wdl and globulin 2.7 g/dl. Tests for anti-smooth muscle
and antimitochondrial antibodies were positive. Antinuclear factor also
was strongly positive. Serum 1gM was 250 mgldl (normal, below 180
mg/dl); IgG, 235 mg/dl (normal, below 146 mg/dl); and IgA, 515 mg/dl
(normal, below 420 mg/dl). A liver biopsy at that time showed distortion
of the normal lobular architecture with formation of mieronodules. The
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portal spaces were fibrotic and heavily infiltrated with lymphocytes
together with some plasma cells and eosinophils. The inflammatory
infiltrate invaded the lobules causing piecemeal necrosis of liver cells.
There were signs of cholestasis within the distorted bile ducts, and bile
pigments were found in the liver cells. Orcein staining gave a positive
reaction for copper in moderate amounts. These findings were consid-
ered compatible with advanced primary biliary cirrhosis.
Two years ago peripheral edema and aseites appeared for the first
time. The blood pressure was 110/60 mm Hg and the total serum
bilirubin was 6.7 mg/dl (60% conjugated). Serum albumin was 2.5 g/dl
and serum globulin was 4.5 g/dl. Serum creatinine was 0.9 mg/dl and
serum calcium 8.2 mg/dl. Spironolnctone and furosemide produced a
diuresis with marked improvement in the edema and ascites. Vitamins
A, D, K, and B complex also were given. A few months later she
developed hepatic encephalopathy, and treatment with lactulose and
oral neomycin was started, One year ago her ascites became increasing-
ly resistant to combined treatment with bed rest, a salt-poor diet, and
diuretics. The use of a Le Veen shunt was considered but had to be
postponed.
She was readmitted six months ago because of anasarea and deep
coma. The blood pressure was 100/60 mm Hg. Anemia and pancyto-
penia were present and the prothrombin time was grossly prolonged.
Total bilirubin was 5.3 mg/dl and the SGOT was 65 U. Serum sodium
was 119 mEq/liter; potassium, 4.1 mEq/liter; bicarbonate, 18 mEq/liter;
chloride, 85 mEq/liter; osmolality, 260 mOsmlkg; BUN, 30 mg/dl;
ereatinine, 3.5 mg/dl; and albumin, 1.5 g/dl. The 24-hr urine volume was
350 ml with an osmolality of 400 mOsmlkg and a sodium concentration
of 5 mEq/liter. Several days after admission she died following a
massive gastrointestinal hemorrhage. Her clinical course is depicted in
Figure 1.
Discussion
DR. ORI S. BETTER (Chief, Department of Nephrology,
Rambam Hospital; Annie Chutick Professor of Medicine, and
Member, Rappaport Family Institute for Research in the Medi-
cal Sciences, Faculty of Medicine, Technion-Israel Institute of
Technology, Haifa, Israel): The patient under discussion had
primary biliary cirrhosis (PBC) proved by liver biopsy with
characteristic cholestatic jaundice and serologic and immuno-
logic abnormalities. The beginning of the disease with sicca
syndrome and itching in a woman in the fifth decade, and the
protracted phase of benign cholestasis are typical for this
disease. Severe complications secondary to advanced cirrhosis
began to appear more than 20 years after the onset of the first
clinical manifestations of the disease. Among them were portal
hypertension 5 years ago and, 3 years later, edema, ascites, and
hepatic encephalopathy. The edema and ascites initially re-
sponded to conventional therapy but after one year became
increasingly refractory to treatment. On her final admission 25
years after the apparent onset of the disease, she developed
arterial hypotension and the hepatorenal syndrome. The termi-
nal event was a massive gastrointestinal hemorrhage.
The disease course in this patient allows us to discuss some
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Fig. 1. Clinical course of the patient under
discussion. Not shown here are levels of
blood alkaline phosphatase that were elevated
between two and three times the upper normal
range throughout the course. The blood pres-
sure between 1960 and 1982 was 140/90 mm
Hg and showed a tendency to decline after
1982. In the final admission, blood pressure
was 100/60 mm Hg. During this admission she
developed the hepatorenal syndrome and died
of massive gastrointestinal hemorrhage.
aspects of the disturbed volume regulation in cholemia and in
cirrhosis, two common conditions that predispose patients to
renal failure. Renal involvement in advanced liver disease was
discussed in two previous Nephrology Forums [1, 21 and in an
editorial in Kidney International [3]. I therefore will focus this
discussion on the effects of chronic liver disease and cholestasis
on the kidney and on the circulation, effects that have not yet
received adequate attention. The main questions I will address
here are: (1) Why are edema and ascites such late complications
in patients with PBC? (2) Is bile per se nephrotoxic? (3) What
role does cardiovascular dysfunction play in the severe renal
insufficiency that complicates advanced chronic liver disease?
Salt retention in primaly biliary cirrhosis
In contrast to Laennec's cirrhosis, in which edema and
ascites occur even in moderately advanced stages of the dis-
ease, salt retention is a late complication in PBC [4, 5]. There
are several explanations. Because PBC progresses slowly and
causes predominantly cholestasis rather than parenchymal liver
damage, liver architecture and metabolic functions remain
spared for many years. The major causes of disturbed volume
homeostasjs such as hypoalbuminemia and portal hypertension
are late complications. As I noted before, edema and ascites
developed in this patient more than 20 years after the onset of
the disease, only when hypoalbuminemia appeared. Although
portal hypertension was present for at least 3 years, it alone did
not cause sodium and water retention. We believe that factors
independent of prolonged preservation of normal liver function
keep the patient with PBC free of edema until late in the
disease. Studies from our laboratory show that when patients
with PBC are challenged with a standardized intravenous
volume load, they exhibit an exaggerated natriuretic response,
the mean of which is twofold greater (P < 0.001) than that in
normal subjects [6]. By contrast, patients with compensated
Laennec's cirrhosis have a blunted natriuretic response to such
a volume challenge. Simultaneous investigation of renal han-
dling of phosphate and free water formation suggests that the
site of the exaggerated natnuretic response to volume expan-
sion in PBC occurs proximal to the diluting segment [61. These
observations have prompted us to suggest that a natriuretic
factor contributes to keeping patients with PBC free of edema
until the disease reaches an advanced stage. When we first
made these observations in 1977, we were not aware of any
explanation for the exaggerated natriuresis in PBC. However,
we now know that the liver is a prerequisite for normal
natriuresis. Vascular exclusion of the liver in the dog [7] and
partial hepatectomy in the rat [8] abolish the normal natriuretic
response to volume expansion. These findings, and the obser-
vation that intraportal infusion of saline causes greater natriure-
sis than does systemic intravenous infusion, raised the hypothe-
sis that the liver contains sodium receptors and that it elabo-
rates a natriuretic factor (reviewed in [9]). Such sensory
function of the liver is teleologically advantageous. The liver is
the first organ to "see" changes in portal blood tonicity
following a meal or ingestion of water. Theoretically, increased
production of hepatic natriuretic factor in primary biliary cir-
rhosis could account for the supranormal natriuretic response.
Nonetheless, we have no basis for such an assumption. Other
mechanisms might well be operative.
We have proposed that pronounced renal effects of high
plasma concentrations of bile can explain both the exaggerated
natriuresis in PBC and the lack of salt and water retention until
late stages of the disease. The striking destruction of the bile
ducts in PBC causes cholestasis with retention of bile constitu-
ents in the circulation. Bile has a natriuretic effect when
injected intravenously in the dog [10]. These studies were
extended by Alon et al in our laboratory [11] (see Figs. 2 and 3).
We showed that intrarenal infusion of dilute bile caused a
pronounced natriuresis without affecting GFR or renal plasma
flow. Further studies showed that bile salts rather than bilinibin
were responsible for the natriuretic action of bile [11]. Even
more striking were the observations by Levy and Finestone,
who showed that acute (4-hour) obstruction of the common bile
duct in the dog caused not only pronounced natriuresis but also
a significant increase in GFR and renal plasma flow [12]. They
confirmed our findings that bile salts were the compounds
responsible for the natriuresis [13]. Moreover, intrarenal infu-
sion of bile salts in the dog was not followed by an increase in
GFR and renal plasma flow [11, 13]. Therefore, the hepatobili-
ary factor that increases GFR and renal plasma flow during
acute biliary obstruction in the dog remains elusive. Thus
retention of bile salts during acute cholestasis apparently aug-
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ments natriuresis. We propose that an increase in circulating
bile salts promotes natriuresis in PBC and that this natriuretic
effect might contribute to the long delay in the appearance of
edema and ascites. In acute biliary obstruction, retained bile
salts might produce renal sodium wasting and volume deple-
tion, thus aggravating other common volume losses caused by
vomiting, diarrhea, and insensible water loss due to fever.
Circulating bile salts thus might contribute to hypovolemia and
to a type of "prerenal" azotemia.
Is bile nephrotoxic?
Several investigators have noted that patients with obstruc-
tive jaundice have an increased risk of postoperative renal
failure [14—171. Moreover, the greater the degree of preoper-
ative hyperbilirubinemia, the greater the risk of renal failure
[14]. In experiments with rats subjected to bile duct ligation,
Baum, Sterling, and Dawson suggested that conjugated hyper-
bilirubinemia sensitized the kidneys to anoxic damage [18]. In
contrast, Aoyagi and Lowenstein proposed that bile salts rather
than bilirubin aggravate the ischemic damage in the rat kidney
[19]. Our studies and those of Levy et a! clearly show that in the
normal dog direct intrarenal infusion of bile in dilutions greater
than 1:10 and at a rate of 1 ml]min does not impair GFR or renal
plasma flow [11—13] (see also Figs. 2 and 3). Moreover, acute
bile duct ligation actually increases GFR and renal blood flow in
the dog [12]. Preliminary studies in our laboratory showed that
intrarenal infusion of dilute bile into the dog increased renal
production of prostaglandin E2 (PGE2). Furthermore, indo-
methacin abolished both the natriuresis and the increase in
renal PGE2 synthesis associated with intrarenal infusion of bile
(Alon U, Davidai G, Berant M, Mordechovitz D, Better OS,
unpublished observations).
All these experiments suggest that moderate cholemia is not
nephrotoxic. This may partly answer the question raised by
Papper: does jaundice contribute to precipitation of the hepa-
torenal syndrome (HRS)? In Papper's extensive personal series
of 200 patients with HRS, progressive jaundice preceded the
occurrence of HRS in 40% of the patients [201. Our results in
the dog suggest that increasing jaundice as a prelude to the HRS
in humans is a marker of deteriorating liver function but that
high bilirubin concentrations are not nephrotoxic.
Cardiovascular dysfunction in liver disease
After 23 years of illness, the patient we are discussing here
began to be hypotensive (blood pressure, 110/60 mm Hg versus
140/90 mm Hg in previous years). What was the reason for this
lowering of arterial blood pressure? There are multiple causes
of hypotension in chronic liver disease (Table 1) [3]. In addition
to maldistribution of blood, interstitial fluid, and hepatic lymph,
a disturbance within the blood vessels themselves renders them
resistant to vasoactive agents. This inherent vascular dysfunc-
tion can be observed not only in vivo [2 1—23] (see also Fig. 4),
but also in vitro in isolated arteries, veins, and vasa deferentia
taken from animals subjected to chronic bile duct ligation [24,
25]. The reason for this resistance to pressor agents has not
been clarified. It can be mimicked by the addition of dilute bile
or bile acids to the in-vitro perfusates of these blood vessel
preparations [241. Blunting of the pressor response is achieved
in the isolated portal vein of the rat with bile acids in micromo-
lar concentrations [24], Concentrations of circulating bile acids
of this magnitude occur in obstructive jaundice in humans. The
portal vein might be sensitive to such a low concentration of
bile acids because of its unique exposure to bile acids that are
absorbed from the gut. I conclude that bile acids, in addition to
their influence on volume, might contribute to vasodilation and
induce hypotension.
Myocardial dysfunction also can be a major contributor to
hypotension in liver disease. Diminished venous return due to
tense ascites [261, alcoholic myopathy, and malnutrition all can
interfere with myocardial performance. Gould et al carried out
cardiac catheterization in 10 patients with cirrhosis who had a
presystolic gallop [27]. When exercising, all 10 patients showed
an average increase in left ventricular end-diastolic pressure
from 6.0 to 19.0 mm Hg (an increase of 216%). A striking
increase also was noted in pulmonary artery pressure (24 to 47
mm Hg; +96%). This observation, coupled with the finding that
correction of the hypotension with vasopressors may precipi-
tate pulmonary edema in patients with cirrhosis (28), suggests
that some patients with cirrhosis have latent congestive heart
failure that is ameliorated by the decrease in afterload brought
about by peripheral vasodilation. In these two clinical studies
[27, 281, however, the contribution of chronic alcoholism to
myocardial dysfunction cannot be excluded.
NaCI
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collection
Fig. 2. Diagrammatic sketch of the experimental procedure of intrare-
nal bile infusion in the dog, Bile is infused intrarenally into the
experimental kidney. Urine is collected individually from each kidney.
The contralateral kidney serves as control. Inulin and PAM clearances
as well as central venous pressure and arterial pressure are monitored.
(Adapted from Ill].)
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Fig. 3. Effect of unilateral infusion of diluted bile on the flow of urine and on the rate of electrolyte excretion. Note the ipsilateral increase in the
flow of urine and electrolyte excretion during the intrarenal infusion of bile. Infusions were: A, 0.9% NaCI; B, bile diluted 1:20; C, bile diluted 1:10,
D, 0.9% NaCI. Cross-hatched columns represent the ipsilateral (experimental) kidney, open columns the contralateral (control) kidney. < 0.05
(versus A); "P < 0.01 (versus A). Results are expressed as means SD. (Reprinted by permission from Clin Sci, © 1982, The Biochemical
Society, London [11].)
As is well known, alcoholism is associated with alcoholic
cardiomyopathy as well as with a characteristic decrease in the
concentration of blood calcium, magnesium, inorganic phos-
phate, and potassium. All these changes, by themselves, could
adversely affect cardiac function. Moreover, intracellular skele-
tal muscle content of calcium and sodium is increased and that
of phosphate, magnesium, and potassium is decreased. These
changes are conducive to the development of rhabdomyolysis
of chronic alcoholism, as described by Knochel [291. It is
conceivable that parallel changes in intracellular electrolyte and
mineral content occur also in the myocardium. To further
clarify the effect of liver damage on cardiac function in the
absence of interference by chronic alcoholism, we studied
myocardial performance in two canine experimental models:
dogs with choledochocaval anastomosis (CDCA), a model that
produces isolated cholemia [3011, and dogs with chronic bile duct
ligation (CBDL) [31—33], a model that produces extensive liver
fibrosis. The latter canine model (CBDL) closely resembles
Laennec's cirrhosis in humans and is accepted as such by
hepatologists (see Table 2). The CDCA dogs had extreme
cholemia (bilirubin 40—60 mg/dl) but minimal parenchymal
damage. We studied the effect of cholemia on multiple parame-
ters of cardiac function in unanesthetized trained animals [34,
35]. These measurements included: (1) systolic time intervals;
(2) pre-ejection period (PEP), which estimates the rate of
ventricular pressure development [36, 37]; (3) left ventricular
ejection time (LVET), which estimates stroke volume; and (4)
dP/dt, a measure of the rate of increase in systolic pressure over
time. We found that cholemia was associated with a twofold
prolongation of PEP, a 15% shortening of LVET, an increase in
the ratio of PEPILVET, and a decrease in dP/dt. All these
changes were statistically significant and suggested impairment
in myocardial contractility [36, 38].
We extended these in-vivo studies by measuring in vitro the
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Table 1. Factors causing underfihling of the circulation in chronic liver
disease in humans and in experimental animals
Peripheral vasodilation and blunted vasoconstrictor responses to
reflex, chemical, and hormonal influences.
2. Opening of arteriovenous and portal-systemic shunts.
3. Increase in the vascular capacity of the portal as well as the
nonportal circulation.
4, Loss of fluid from the vascular compartment associated with
hypoalbuminemia and decreased oncotic pressure.
5. Diminished venous return due to tense ascites.
6. Impaired left ventricular performance.
7. Occult gastrointestinal bleeding from ulcers, gastritis, or varices.
8. Volume losses due to vomiting, diarrhea, and excessive use of
diuretics.
ANG II Infusion rate, pmol mm kg
Fig. 4. Increase in mean arterial pressure (mm Hg) in response to
intravenous infusion of angiozensin II (ANG II) before (S---•), I week
(O---O), and3 weeks (fl--.-- El) after ligation of the common bile duct in
conscious dogs. Results shown are means SEM. For control and 1
week data, n = 6; at 3 weeks, n = 5. Similar findings were obtained for
noradrenaline infusion. Note blunting of pressor response to angioten-
sin II following bile duct ligation in these conscious dogs. (Reprinted by
permission from Clin Sci, © 1981, The Biochemical Society, London
[23].)
contractile response to the beta-adrenergic agonist isoprotere-
nol in trabecular heart muscle taken from dogs with either
CDCA or CBDL [37] (see Figs. 5, 6A, 613). We found that the
inotropic response to isoproterenol was blunted in the myocar-
dial tissue obtained from both these models. Analysis of the
data suggested that the blunted response to isoproterenol
involved interferences with the binding of this agent to its
membrane receptor. These findings are consistent with the
preliminary reports by Lebrec and coworkers that there is
resistance to the positive chronotropic action of isoproterenol
in patients with cirrhosis and in rats with chronic bile duct
ligation [39, 40].
Our studies have also shown that bile salts in concentrations
of l0 to 10—6 molar depressed the contractile force of
electrically stimulated myocardial tissue taken from normal rats
(Binah 0, Bomzon A, Better OS, unpublished data). Electro-
physiologic studies in these experiments demonstrated that bile
acids shortened the duration of the action potentials. This
observation suggests that bile acids interfered either with the
Table 2. Characteristic pathophysiologic features of the canine,
chronic bile-duct ligation model that mimic those in patients with
Laennec' s cirrhosis
1. Liver histology showing bridging fibrosis and nodular formation
[33]a
2, Peripheral vasodilation and arterial hypotension [32, 33].
3. Increased cardiac output [32, 331.
4. Intrahepatic and portal hypertension with portal-systemic shunting
[33].
5. Avid salt and water retention with formation of ascites and edema
[311.
6. Impaired urinary dilution [31].
7. Blunted pressor responsiveness to the action of angiotensin II and
norepinephrine [231.
8. Reversible renal failure following administration of nonsteroidal
antiinflammatory agents [57].
a Numerals in brackets are reference numbers.
300
Fig. 5. Representative records showing the effects of isoproterenol (iso)
on the in-vitro isometric twitch from ventricular muscle from chronic
bile duct-ligated dogs (CBDL) and from sham-operated dogs (SO).
Basic cycle length of electrical stimulation = 2000 ms. In the lower
panel, note different calibration for the extreme right record. Active
tension is reduced in the myocardial tissue from CBDL dog. (Reprinted
by permission from C/in Sci, © 1985, The Biochemical Society, London
[371.)
entry of calcium ions into, or with the exit of potassium from,
the myocardial cells.
Taken together, these studies show that chronic liver dam-
age, cholemia, or both exert a vasodepressor and cardiodepres-
sor influence. Increase in circulating bile salts during cholesta-
sis contributes to this phenomenon, but other, as yet unidenti-
fied, biliary compounds [13] as well as endotoxemia [41] and an
increase in circulating leukotrienes [42, 43] also have a cardio-
depressor influence.
The studies I have cited make it possible to formulate a
comprehensive hypothesis regarding the clinical course of the
patient under discussion. I propose that she was protected from
salt retention for years by the natriuretic activity attributable to
increased circulating bile salts. When, after 23 years of illness,
hypoalbuminemia and portal hypertension appeared, this natri-
uretic tendency was overwhelmed by factors summarized in
Table I, and avid sodium and water retention led to the
formation of ascites and edema. In her final admission she was
hypotensive; this complication can be attributed not only to
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Fig. 6. Effect of isoproterenol on isometric twitch indices from sham-
operated and chronic bile duct-ligated dogs. A Active tension. B
Maximum rate of tension activation (+ dT/dt). Abscissa, molar concen-
trations of isoproterenol; ordinate, % change in a given variable
compared with control; •, sham-operated dogs (n = 9); 0, chronic bile
duct-ligated dogs (n = 5); A, choledochocaval anastomosed dogs (n =
5). For each twitch parameter, dose-response curves from the control
and any jaundiced groups were compared using two-way analysis of
variance (ANOVA). The P value for the ANOVA test is shown on the
right-hand side of the figure (6A and 6B). Student's 1-test was used to
compare individual doses: * < 0.01; tP < 0.05. Note: attenuation of
indices of contraction in myocardial tissue taken from CBDL dogs.
(Reprinted by permission from Clin Sci, © 1985, The Biochemical
Society, London [37].)
redistribution of extracellular fluid, but also to vasodepressor
and cardiodepressor influences of cholemia. The cardiovascular
depressor effect aggravated the underfilling of the circulation
and contributed to the development of the hepatorenal syn-
drome late in her course. It is noteworthy that despite the
severe azotemia (serum creatinine 3.5 mgldl), the kidney was
able to concentrate the urine above the osmolality of the plasma
and absorbed sodium avidly, a pattern that is consistent with
functional renal failure.
I have discussed today the course of a patient with PBC. This
interesting disease comprises only 2% of all instances of cirrho-
sis in humans. What implications from our animal studies can
be extrapolated to the much more common affliction of alcohol-
ic cirrhosis? Alcoholic cirrhosis is, of course, one of the leading
causes of death during the years of gainful employment in the
United States and Europe. As Table 2 illustrates, the dog with
established CBDL is a useful experimental model for Laennec's
cirrhosis in humans (even though, in the first postoperative
week, the findings are more reminiscent of obstructive jaun-
dice). Thus, the CBDL dog allows one to study longitudinally
the pathophysiology of early cirrhosis. Our in-vivo and in-vitro
studies cited today in the CBDL dog clearly show that the entire
cardiovascular tree is depressed in this condition and thus
presumably in Laennec's cirrhosis as well. Such effects would
contribute further to the adverse influences of alcoholic cardio-
myopathy, malnutrition, and cholemia on the circulation in
patients with cirrhosis. The resulting cardiovascular depression
contributes to the underfilling of the circulation and to arterial
hypotension. In moderately advanced cirrhosis this functional
disorder leads to the "prerenal" pattern, with avid sodium and
water retention. In advanced cirrhosis, "underfihling" along-
side the factors listed in Table 1 is the background on which the
hepatorenal syndrome or even acute tubular necrosis occurs.
I would like to end this discussion by acknowledging that my
interest in liver-kidney interrelationships was inspired by the
extensive contribution to this field by the late Solomon Papper
who died on 19 August 1984. His personal courage and affirma-
tion of life even in the face of impending death are evident in the
posthumously published article entitled "Care of patients with
incurable chronic neoplasm. One patient's perspective" [44].
Questions and answers
DR. JEROME P. KASSIRER: You showed a series of events that
occur in the course of progressive liver disease that can cause
an acute decline in renal function. The patient with primary
biliary cirrhosis whom you described today remained stable
with normal renal function for many years. Typically, in the
patient with alcoholic cirrhosis, deterioration in renal function
is preceded by hypovolemia, secondary to the use of a diuretic
or to paracentesis. In the final stage, your patient had no overt
signs of heart disease, no reasons for nutritional or alcoholic
cardiomyopathy, and the jaundice was stable. I don't under-
stand why she suddenly developed the hepatorenal syndrome.
Could you speculate on this question?
DR. BETTER: As is often the case, the hepatorenal syndrome
may manifest itself in advanced liver disease without an appar-
ent precipitating cause. At the end of her long illness, she was
frankly cirrhotic. There was total distortion of the architecture
of her liver, with deterioration of parenchymal liver function,
and she had hypoalbuminemia and portal hypertension, which
led to tense ascites. Thus, she behaved like many patients with
end-stage cirrhosis.
Many of the factors enumerated in Table 1 operated in this
patient to impair systemic hemodynamics and thereby to com-
promise renal function. It is difficult to pinpoint the exact cause
of the hepatorenal syndrome, but if jaundice contributed to it,
perhaps it was through an adverse effect on the circulation
rather than via a direct effect on the kidney.
DR. KASSIRER: You clearly described the diuretic action of
bile salts. Is it possible that the diuretic effect is related to the
effect of the bile acid as a large anion? Is it the same as giving a
load of nonreabsorbable anion, such as phosphate or sulfate, to
a patient who is avidly retaining salt? Under such circum-
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stances there is an increase either in hydrogen, potassium, or
even in sodium in the urine. Could bile acids act as nonreabsor-
bable anions rather than as a diuretic?
DR. BETTER: The fact that intrarenal bile is still diuretic even
at a dilution of 1:250 [13) renders this possibility unlikely. The
concentration of nonreabsorbable anion at such dilution in the
tubular fluid should be negligible. I therefore believe that bile
salts act pharmacologically like a diuretic rather than like
sulfate or phosphate, or osmotically like mannitol.
DR. 0. ZINDER (Chief, Laboratory for Clinical Biochemistry,
Rambam Hospital): There were reports that bile acids interfere
with the action of sodium-potassium ATPase [45]. Is it possible
that bile acids in your models interfere with sodium-potassium
ATPase activity in the heart muscle or in the kidney? If so, it
could explain cardiac and renal dysfunction as well as the
increase in intracellular sodium that you quoted as being
present in cirrhosis.
DR. BETTER: Your point is well taken. There are data
suggesting that an increase in bile salts in the gut interferes with
sodium-potassium ATPase activity and thus decreases sodium
reabsorption and, secondarily, water reabsorption and thus
causes diarrhea [45, 461. Similarly, an increase in circulating
bile acids could interfere with the activity of this enzyme in the
brain and aggravate the metabolic disturbance of hepatic coma,
partially by increasing the sodium content of brain cells [47].
We did not study the sodium-potassium ATPase activity of
tissues during jaundice. We believe that the natriuretic action of
bile acid is mediated by increased synthesis of renal POE2
rather than by blocking of the sodium-potassium ATPase. A
circulating, ouabain-like sodium pump inhibitor (natriuretic
hormone) was proposed by de Wardener [48], Haddy [49], and
Blaustein [501 as the cause of some forms of hypertension. This
hormone is thought to block sodium extrusion from cells
leading to an increase in intracellular sodium and, secondarily,
also calcium. Such a change in intracellular composition would
increase vascular smooth muscle contractility and thus increase
total peripheral resistance. In chronic liver disease, however,
we have the exact opposite situation, namely, vasodilation,
hypotension, and antinatriuresis. So if a circulating inhibitor to
sodium-potassium ATPase is increased in cirrhosis, its physio-
logic action on the heart and kidney is masked.
PROF. H. E. ELIAHOU (Chief, Department of Nephrology,
Chaim Sheba Medical Center, Tel Aviv): Many paradoxes were
raised by your discussion and I wonder how you will reconcile
them. (1) If your proposition is that bile salts can act on the
heart in a similar fashion to calcium channel inhibitors, then
they should be protective to the kidney. We and others have
shown that such agents protect against experimental acute renal
failure, Yet we all know that jaundiced and cirrhotic patients
are susceptible to acute renal failure. (2) You spoke loosely
about acute renal failure occurring in end-stage cirrhosis and in
cholemia. Yet you described the prerenal nature of renal failure
and not acute tubular necrosis, in which the urine is isoosmotic
and sodium excretion increased. Could you clarify these
paradoxes?
Da. BETTER: Yes, indeed, we have a paradox. Several effects
of high circulating bile acids should protect the kidney from
acute tubular necrosis in patients with advanced cirrhosis and
cholemia. They include (1) nifedipine-like effect, and (2) stimu-
lation of renal PGE2 synthesis and decreased coagulability of
the blood. Yet such patients are prone to ATN. I believe the
reason is that the maldistribution of blood and interstitial fluid
as well as the vaso- and cardiodepressor effect of cholemia
cause an "underfilling" of the circulation and hypotension (see
also Table 1), which in turn cause prerenal failure. When this
situation is protracted, any protective influences on the kidneys
are overridden, and prerenal failure will be transformed into
ATN. The vasoconstrictor influences of endotoxin [41] and
renal thromboxane A [511 may mediate such a transition. It is,
however, the metabolic and hemodynamic environment rather
than parenchymal renal disease that leads to this renal failure.
When the metabolic and hemodynamic environment is normal-
ized by successful liver transplantation [52], or by transplanta-
tion of hepatorenal kidneys into recipients with normal livers
[53], renal function improves. In other words, the hepatorenal
syndrome is reversed.
DR. KASSIRER: Would you argue that the heart is at fault in
the hepatorenal syndrome?
DR. BETTER: Not only the heart but the entire cardiovascular
system is depressed in the hepatorenal syndrome. In this
disorder arterial hypotension is due predominantly to decreased
peripheral resistance. Myocardial dysfunction is present but
plays a lesser role in decreasing blood pressure.
DR. A. HARAMATI (Visiting Scientist, Department of Physiol-
ogy and Biophysics, Mayo Clinic and Mayo Foundation, Roch-
ester, Minnesota, USA): You made the statement that in
experiments performed by Dr. Un Alon of your laboratory,
indomethacin blocked the diuretic effect of bile salts. Indeed, a
rise in PGE2 would explain both the increase in renal blood flow
and the natriuresis. Are you reasonably convinced that the
diuretic effect of bile salts is mediated by PGE2? You were not
clear about such a connection. We are left with the impression
that bile salts are directly diuretic and that the increase in
urinary POE2 is a secondary phenomenon.
DR. BETTER: We believe that bile acids are natriuretic by
virtue of their stimulation of renal PGE2 synthesis. Similar
doubts exist concerning the effects of indornethacin on the
diuretic action of furosemide in normal humans and animals.
Depending on the sodium balance of the individual and the
dosage of indomethacin, you can block the natriuretic effect of
furosemide with this drug. The results of these experiments in
the literature are not clear-cut [54]. But the situation in patients
with cirrhosis is unequivocal. In cirrhosis, nonsteroidal antiin-
flammatory agents abolish the natniuretic action of furosemide
[551.
DR. HARAMATI: Could some of the derangements in volume
control and renal handling of sodium that you described today
be due to a disturbance in the excretion of copper in a patient
with primary biliary cirrhosis?
DR. BETTER: The hepatobiliary system is the main excretory
route for body copper. In biliary cirrhosis, destruction of the
intrahepatic biliary ducts results, among other things, in reten-
tion of copper and in an increase of blood and tissue copper,
similar to that in Wilson's disease. The pathologist found an
increase in copper content of the liver in the patient described
today. One would expect an increase in copper also in bone,
heart, and kidney. This might explain the severe osteopenia that
occurs in biliary cirrhosis and that complicates the vitamin D-
dependent osteomalacia in this disease. Copper deposits in the
tubules—analogous to what occurs in Wilson's disease—can
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cause proximal and distal tubular acidosis and perhaps also the
exaggerated natriuresis that we have described in primary
biliary cirrhosis.
DR. J. BERNHEIM (Chief, Department of Nephrology, Bet
Meir Hospital, Kfar Saba, Israel): I'd like to return to the role
of PGE2 in the natriuresis induced by bile salts. The increase in
natriuresis and in PGE2 excretion that you found following
intrarenal injection of bile was abolished by indomethacin; this
observation is not necessarily proof that the diuretic effect of
bile is PGE2 mediated. There are many discrepancies between
urinary PGE2 excretion and natriuresis. In cirrhosis, urinary
PGE2 is high, yet the kidney retains sodium. Changes in PGE2
excretion can be nonspecific and are influenced by the urine
volume. In your experiments, changes in urinary PGE2 excre-
tion could merely reflect fluctuation in urine volume. I do not
believe that a decrease in both urinary PGE2 and sodium
excretion following indomethacin in your experiments neces-
sarily proves a causal connection between renal PGE2 synthesis
and natriuresis.
DR. BETTER: This issue is not yet settled. I do know that
Wernze and Goerig in West Germany regularly find that the
levels of urinary PGE2 are greater in primary biliary cirrhosis
than in Laennec's cirrhosis (personal communication, 1985).
DR. A. BOMZON (Department of Pharmacology, Faculty of
Medicine, Technion-Israel Institute of Technology, Haifa):
From what we heard today, bile salts appear to be magic
substances having a variety of interesting influences. They
block sodium-potassium ATPase, inhibit calcium influx, and
interfere with adrenergic receptors. In the experiments of Binah
eta! that you described [37], the effects of bile salts were seen at
concentrations of iO M. What were the concentrations of bile
salts in the experiments that showed a natriuretic effect of bile?
DR. BETTER: Acute bile duct ligation or choledochocaval
anastomosis in our hands regularly causes an immediate, strik-
ing diuresis in the dog. Levy calculated the increase in bile salts
in the blood following acute bile duct ligation in the dog and
found it to be in the micromolar range [12, 13]. Thus, although
Alon et al may have injected a pharmacologic dose of bile salts
intrarenally, these compounds also are natriuretic in the physio-
logic range.
DR. KASSIRER: You assume that the entire effect on the
kidney is due to bile salts. How can you be sure that other
substances are not having an effect?
DR. BETTER: I believe that the natriuretic effect is due to bile
salts, because removing them from bile by dialysis or absorp-
tion with cholestyramine abolishes the natriuretic activity of
bile [131. Bile acid, however, is not the factor in bile that is
capable of increasing glomerular filtration rate and renal plasma
flow after acute bile duct ligation. The nature of the bile
compound that has vasodilatory properties remains unknown.
DR. U. ALON (Department of Pediatric Nephrology, Ram-
barn Hospital): Although jaundice interferes with cardiac per-
formance, the main reason for the hypotension is peripheral
vasodilation. Do you have an explanation for this disorder and
for the blunted response to pressor agents in chronic liver
disease?
DR. BETTER: Your point is well taken. Peripheral vasodila-
tion is the main cause of the hypotension in liver disease; the
heart plays only a secondary role. The reason for the vasodila-
tion is not clear. One possible explanation is that vasodilatory
hormones from the intestines (such as glucagon, VIP, and
substance P) bypass the liver or are inadequately degraded by
the diseased liver and escape into the circulation. Thus, the
systemic circulation is exposed to enhanced vasodilator activi-
ty. Another possibility is an increase in prostacyclin synthesis
within the arteriolar wall. Such a possibility is supported by the
finding of an increase in vascular responsiveness to angiotensin
II in patients with cirrhosis who received indomethacin [56] and
by the finding of an increase in arterial blood pressure in
anesthetized, bile duct-ligated dogs following indomethacin
administration [57]. Dr. Bomzon, are there any known explana-
tions for the peripheral vasodilation of cirrhosis?
DR. BoMzoN: Patients with cirrhosis have increased sympa-
thetic tone as well as an increase in circulating catecholamines,
yet they are hypotensive. This finding emphasizes the end-
organ refractoriness to constrictor influences, be it the vascular
smooth muscle or even the myocardium. The mechanism for
this effect has not been defined.
DR. BETTER: I would like to add that humans and animals
with liver disease are hypotensive in the presence of an increase
in circulating angiotensin II, arginine vasopressin, and catechol-
amines, all powerful vasoconstrictors under normal conditions.
Finding elevated levels in the presence of moderate hypoten-
sion does not mean that these hormones do not participate in
the defense of blood pressure; blocking their activity can
precipitate much more profound hypotension in patients with
liver disease.
DR. P. SZYLMAN (Chief, Division of Nephrology, Poriah
Hospital, Tiberias, Israel): You utilized phosphate clearance as
a marker for proximal tubular function in your experiments in
patients with biliary cirrhosis. Is the use of phosphate clearance
for this purpose justified in this disease, given the aberration in
vitamin D metabolism that occurs?
DR. BETTER: Vitamin D metabolism is grossly disturbed in
biliary cirrhosis [58]. A lack of bile acids in the gut interferes
with the absorption of fat and the fat-soluble vitamins A, D, E,
and K. Steatorrhea, by itself, also diminishes calcium absorp-
tion. The diminished quantity of vitamin D that is absorbed may
not be adequately hydroxylated by the diseased liver and can
result in subnormal levels of 25(OH)D and its active metabo-
lites. It is no wonder that patients with biiary cirrhosis are
hypocalcemic and can suffer from florid osteomalacia. I agree
with you that under the influence of secondary hyperpara-
thyroidism and hyperphosphaturia characteristic in this condi-
tion, the renal clearance of phosphate is not a good marker for
proximal tubular function.
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